RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.

RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

By Yang Xite This year marks the 33rd anniversary of the establishment of diplomatic relations between China and Israel. Amid the current...

Palo Alto Networks' FCF margin rose to 25.3% in Q3 as AI platforms drive scale and multi-product deals build long-term momentum.

OXY's strategic acquisitions and high-margin Permian assets fuel long-term growth.

OXY's strategic acquisitions and high-margin Permian assets fuel long-term growth.

TBLA ramps up AI-focused R&D to enhance ad targeting, boost innovation and fuel long-term growth in a fast-evolving market.

APP and DUOL leverage AI-driven platforms to fuel rapid revenue growth and offer strong short-term price upside potential.

APP and DUOL leverage AI-driven platforms to fuel rapid revenue growth and offer strong short-term price upside potential.

Comfort Systems leans into strategic M&A, backed by strong cash and a $6.9B backlog, to drive focused long-term growth.